#387 - AMA #83: Peptides—evaluating the science, safety, and hype in a rapidly growing field

What It Covers

Peter Attia presents a structured framework for evaluating gray market peptides—including SS-31, Melanotan II, CJC-1295, and BPC-157—by examining mechanism of action, human safety data, efficacy evidence, and whether FDA-approved alternatives exist before considering any peptide for personal use.

Key Questions Answered

• •Evaluation Framework: Apply five questions to any peptide before use: Does a defined mechanistic pathway exist? What downstream effects occur in healthy humans? What does safety data show? How do risks compare to benefits? Are FDA-approved alternatives available? This framework applies equally to approved drugs and gray market compounds.
• •Four-Bucket Classification: Categorize peptides into one of four tiers—no viable use case, viable mechanism but no clinical trials, viable mechanism with ongoing trials but no approved indication, or illegal replicas of FDA-approved drugs sold as research-only compounds. Knowing which bucket a peptide occupies shapes the risk-benefit calculation.
• •Mechanism of Action Standard: Less than 3% of FDA-approved drugs lack a defined mechanism of action—Tylenol, lithium, and Mucinex are rare exceptions. When a peptide vendor cannot articulate specific mechanistic steps beyond vague claims like "boosts energy production," treat that absence as a significant red flag warranting skepticism.
• •Gray Market Reality: Most biohacking peptides are sold under a "research use only" designation, making their sale technically legal while human use remains unapproved. Third-party testing can verify purity but cannot confirm biological activity or long-term safety, meaning sourcing quality remains an unresolved variable for anyone using these compounds.
• •Shifting Goalposts Signal: When a peptide's claimed benefits change repeatedly over time—moving from recovery to longevity to performance to beauty—treat that pattern as evidence of weak underlying science. Legitimate compounds with solid mechanisms maintain consistent, narrowly defined efficacy claims supported by reproducible data rather than evolving marketing narratives.